SEER-Medicare analyses across 2005–2007, 2010–2012, and 2017–2019 showed persistently lower adjusted curative-treatment rates ...
The advent of targeted therapy and immunotherapy has radically transformed the approach to the treatment of non-small cell lung cancer (NSCLC). Treatment choices are now primarily biomarker-driven, ...
Targeted therapy is the use of agents (typically small molecules, but sometimes monoclonal antibodies, or mAbs) to target cancer cells based on unique biomarkers (typically mutations or other ...
In a 2025 JAMA Network Open invited commentary, Melina E. Marmarelis, MD, MSCE, and Lauren Reed-Guy, MD, both of the Perelman School of Medicine of the University of Pennsylvania in Philadelphia, ...
Discover the latest insights on Zongertinib's efficacy and safety for HER2-mutant non-small cell lung cancer, promising new treatment options. Stay ahead of policy, cost, and value—subscribe to AJMC ...
A Yale Cancer Center team completed a multi-institutional analysis of treatment options for patients with newly diagnosed EGFR-mutant non-small cell lung cancer (NSCLC) with brain metastases to ...
BRAF-positive non-small cell lung cancer (NSCLC) treatments can use the BRAF biomarker to provide effective, targeted treatment for this subset of lung cancer. BRAF-positive NSCLC is an uncommon or ...
EGFR tyrosine kinase inhibitors (TKIs) are effective treatments for EGFR-mutant non-small cell lung cancer (NSCLC). However, even after undergoing systemic therapy, patients may have oligometastatic ...
Experimental treatment with CAN-2409 was associated with a median overall survival (mOS) of 24.5 months in patients with advanced NSCLC who had an inadequate response to ICI treatment, failed several ...
The FDA has previously granted fast track designation to aglatimagene plus valacyclovir in combination with ICI therapy for ...
A new study finds Black Medicare beneficiaries with early-stage non–small cell lung cancer (NSCLC) continues to receive curative treatment at lower rates than White patients, highlighting ongoing ...
Zacks Investment Research on MSN
Novocure's Optune Lua gets Japan reimbursement for NSCLC treatment
Novocure NVCR recently announced that Japan’s Ministry of Health, Labour and Welfare has approved reimbursement for Optune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results